The Latest Cardiac and Vascular News
– One in four physicians surveyed feel the “lack of technology or equipment to make an accurate diagnosis of coronary artery disease and peripheral artery disease” is a key obstacle to an accurate diagnosis – Over a third of surveyed patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease […]
EATONTOWN, N.J., Nov. 11, 2021 /PRNewswire/ — Angel Medical Systems, Inc., (dba AngelMed) a company focused on improving long-term management of high-risk coronary disease in patients who have survived one or more heart attacks, announced today the Center for Medicare & Medicaid Services (CMS) has granted The Guardian™ implantable acute coronary syndrome […]
If approved, Jardiance would be the first clinically proven treatment for adults across the full spectrum of heart failure regardless of ejection fraction RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 11, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Jardiance® (empagliflozin) 10 […]
SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2021 and filed its quarterly report on Form 10-Q for the three and nine months […]
WARRINGTON, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the third quarter ended September 30, 2021 and provided key business updates. “I am very pleased to […]
ST. LOUIS, Nov. 11, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2021. “We are proud of the progress made on multiple fronts in the third quarter,” said David […]
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease, today announced the pricing of its initial public offering of 2,750,000 units, each consisting of (i) one share of common stock and (ii) one […]
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the initiation of VICTOR (VerICiguaT in adults with ChrOnic heart failure and Reduced ejection fraction), a pivotal Phase 3 randomized, placebo-controlled cardiovascular clinical trial of VERQUVO® (vericiguat) in patients with chronic heart failure and reduced ejection fraction of 40% […]
Announced topline data from Phase 2b clinical trial of bentracimab, which was conducted in healthy, older volunteers 50-80 years old Reached interim enrollment milestone for the REVERSE-IT Phase 3 trial of bentracimab Prespecified interim analysis of pivotal REVERSE-IT Phase 3 trial to be presented during late-breaking science session on November […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease, announced today the appointment of Dr. Matthew Thompson, as President and Chief Executive Officer. Dr. Thompson will also join Endologix’s Board of Directors. […]
